報價延遲最少15分鐘:2024/12/23 22:13 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.64 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.18/1.06
|
|
企業價值
1.62B
|
| 資產負債 |
|
每股賬面淨值
-3.29
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
1.15B
|
|
每股收益
6.08
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:13 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe. |